Technology
Health
Biotechnology

Equillium

$6.07
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-0.65%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Equillium and other stocks, options, ETFs, and crypto commission-free!

About

Equillium, Inc. Common Stock, also called Equillium, is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. Read More Its product pipeline include EQ001, is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.

Employees
11
Headquarters
La Jolla, California
Founded
2017
Market Cap
106.17M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
38.85K
High Today
$6.25
Low Today
$6.00
Open Price
$6.11
Volume
4.41K
52 Week High
$19.69
52 Week Low
$5.12

Collections

Technology
Health
Biotechnology
Medical
Steel
Metals
Materials
2018 IPO

News

Yahoo FinanceMay 6

Equillium Expands Scientific and Clinical Advisory Team

15

Earnings

-$0.44
-$0.38
-$0.31
-$0.25
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.29 per share
Actual
-$0.34 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.